Insulet to Present at Upcoming Investor Conferences

August 24, 2023

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time):

  • The 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 9:30 a.m.
  • The Baird 2023 Global Healthcare Conference on Tuesday, September 12, 2023 at 2:35 p.m.
  • The Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 1:35 p.m.

To listen to the live audio webcasts of the presentations, please visit Replays of the webcasts will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: and

©2023 Insulet Corporation. Omnipod and Omnipod 5 are registered trademarks of Insulet Corporation.

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717


Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611

Source: Insulet Corporation